doi:10.3969/j.issn.1673-8640.2020.10.018

Abstract

CLC Number:

R446.1

Figures/Tables 3

References 15

[1]	龙辉,刘晓明,曾素芬,等. 正常孕产妇常规凝血指标变化规律的序贯研究[J]. 实验与检验医学,2016,34(1):93-95.
[2]	徐亚玲,常颖,陈叙. 妊娠期糖尿病孕妇妊娠晚期血脂及凝血功能指标检测结果分析[J]. 中国妇幼保健,2017,32(5):951-954.
[3]	LEE M J,PARK S D,KWON S W,et al.Relation between neutrophil-to-lymphocyte ratio and index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention[J]. Am J Cardiol,2016,118(9):1323-1328.
[4]	XU T,WENG Z,PEI C,et al.The relationship between neutrophil-to-lymphocyte ratio and diabetic peripheral neuropathy in type 2 diabetes mellitus[J]. Medicine(Baltimore),2017,96(45):e8289.
[5]	WEN Y,JIN L,JING L,et al.Interactive effects of prepregnancy overweight and gestational diabetes on macrosomia and large for gestational age:a population-based prospective cohort in Tianjin,China[J]. Diabetes Res Clin Pract,2019,154:82-89.
[6]	ARAFA A,DONG J Y.Maternal height and risk of gestational diabetes:a systematic review and meta-analysis[J]. Acta Diabetol,2019,56(7):723-728.
[7]	王昊,漆洪波. 美国妇产科医师学会“妊娠期糖尿病指南(2017)” 要点解读[J]. 中国实用妇科与产科杂志,2018,34(1):62-66.
[8]	袁挺,魏清,周景艺,等. 妊娠糖尿病患者止凝血状态及血小板聚集功能分析[J]. 检验医学,2019,34(9):780-782.
[9]	怀莹莹,李晨波. 妊娠期糖尿病75gOGTT不同时点血糖异常与妊娠结局的相关性分析[J]. 中国妇幼健康研究,2017,28(7):826-828.
[10]	俞晓敏,古航. 高龄孕妇妊娠合并症和并发症临床分析[J]. 第二军医大学学报,2018,39(2):159-164.
[11]	HE X J,QIN F Y,HU C L,et al.Is gestational diabetes mellitus an independent risk factor for macrosomia:a meta-analysis?[J]. Arch Gynecol Obstet,2015,291(4):729-735.
[12]	ANTZA C,CIFKOVA R,KOTSIS V.Hypertensive complications of pregnancy:a clinical overview[J]. Metabolism,2018,86:102-111.
[13]	陈红. 综合护理措施对孕前超重肥胖孕妇妊娠期糖尿病预防效果分析[J]. 中国计划生育学杂志,2017,25(4) :250-253.
[14]	刘石萍,邢会美,苏世萍,等. 单纯空腹血糖升高的妊娠期糖尿病患者的妊娠结局及其影响因素[J]. 中华围产医学杂志,2017,20(11):796-800.
[15]	彭艳,段茉莉,丁桂凤. 妊娠期糖尿病孕期管理与分娩结局的关联性评价[J]. 新疆医学,2017,47(6):604-605.

组别	例数	PT/s		APTT/s		TT/s		Fib/（g/L）
GDM组	213	11.04±0.51		26.94±2.04		16.48±0.67		4.31±0.67^*
对照组	267	11.04±0.64		26.96±1.95		16.46±0.71		4.00±0.71
组别	NLR		BMI/（kg/cm²）		新生儿体质量/g		新生儿1 min Apgar评分/分
GDM组	4.71±4.04^*		26.30±2.97^*		3 433.15±476.23^*		9.97±0.28
对照组	3.84±1.65		25.48±3.23		3 356.22±376.82		9.97±0.22

组别	例数	PT/s		APTT/s		TT/s		Fib/（g/L）
GDM组	213	11.04±0.51		26.94±2.04		16.48±0.67		4.31±0.67^*
对照组	267	11.04±0.64		26.96±1.95		16.46±0.71		4.00±0.71
组别	NLR		BMI/（kg/cm²）		新生儿体质量/g		新生儿1 min Apgar评分/分
GDM组	4.71±4.04^*		26.30±2.97^*		3 433.15±476.23^*		9.97±0.28
对照组	3.84±1.65		25.48±3.23		3 356.22±376.82		9.97±0.22

变量	B值	标准误	Wald χ²值	df值	P值	OR值	95%CI
Fib	0.591	0.142	17.366	1	0.000	1.805	1.367~2.383
NLR	0.121	0.045	7.303	1	0.007	1.128	1.034~1.231
BMI	0.077	0.031	6.214	1	0.013	1.080	1.107~1.147
常量	-5.154	1.000	26.569	1	0.000	0.006

变量	B值	标准误	Wald χ²值	df值	P值	OR值	95%CI
Fib	0.591	0.142	17.366	1	0.000	1.805	1.367~2.383
NLR	0.121	0.045	7.303	1	0.007	1.128	1.034~1.231
BMI	0.077	0.031	6.214	1	0.013	1.080	1.107~1.147
常量	-5.154	1.000	26.569	1	0.000	0.006

组别	例数	早产	产后出血	胎儿宫内窘迫	羊水异常	胎膜早破	巨大儿
GDM组	213	2（0.93）	18（8.45）	10（6.49）	9（4.22）	77（36.15）	22（10.32）
对照组	267	0（0.00）	0（0.00）	7（2.46）	9（3.77）	78（29.21）	13（4.86）
χ²值		2.527	23.196	1.510	0.248	2.698	5.225
P值		0.196	0.000	0.219	0.169	0.101	0.022

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 3

References 15

Related Articles 15

Recommended Articles

Metrics

[1]	FAN Lieying. Research status and application prospects of biomarkers for membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1111-1114.
[2]	SUN Lincheng, LI Jianfeng, CHENG Weili, JI Panyun. Roles of anti-PLA2R IgG4 antibody and PLA2R IgG4/IgG ratio in primary membranous nephropathy [J]. Laboratory Medicine, 2023, 38(12): 1115-1120.
[3]	LIU Qingyang, YUAN Jianming, XIA Jinjun, JIANG Fengying, WANG Qiubo, WANG Xiaoming. CXCL9 as a potential diagnostic marker of rheumatoid arthritis based on GEO database and experimental verification [J]. Laboratory Medicine, 2023, 38(12): 1121-1129.
[4]	YANG Xiao, LI Enling, WU Lixia, DAI Yingxin, WANG Zhiqing, HUANG Hao, ZHENG Bing. Influence of cytoplasmic antinuclear antibody on indirect immunofluorescence assay based antineutrophil cytoplasmic antibody determination [J]. Laboratory Medicine, 2023, 38(12): 1135-1140.
[5]	XIANG Jin, LIU Aiping, HU Yao, WU Zhiyuan, CAO Guojun, GUAN Ming. ANA profiles in COVID-19 patients and influence of serum heat-inactivation on ANA determination [J]. Laboratory Medicine, 2023, 38(12): 1141-1146.
[6]	CHENG Yu, XU Zhen, LU Liu, DING Menglei, YU Shanshan, ZONG Ming, FAN Lieying. Expression and risk factors of anti-ACE-2 antibody in serum of patients with COVID-19 [J]. Laboratory Medicine, 2023, 38(12): 1147-1152.
[7]	. [J]. Laboratory Medicine, 2023, 38(12): 1153-1156.
[8]	. [J]. Laboratory Medicine, 2023, 38(12): 1157-1159.
[9]	WANG Hongling, LIU Mengna, BAI Ping, LIAO Huanjin. Risk factors of relapse following allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia [J]. Laboratory Medicine, 2023, 38(12): 1160-1166.
[10]	YANG Xilan, WANG Jinyu, LIU Shuyu, ZHAN Yiyang, LIU Jing, JIA Jian. Correlation between hyperlipidemia and endothelial microparticles in elderly patients from Gulou Community in Nanjing [J]. Laboratory Medicine, 2023, 38(12): 1167-1172.
[11]	DAI Fangfang, LU Xinxin, YU Yanhua, CHEN Ming, SUN Guizhen. Analysis of Mycobacterium infection in HIV/AIDS patients [J]. Laboratory Medicine, 2023, 38(12): 1173-1176.
[12]	GU Yu, LIANG Xiaoyan, MA Shenghui, TONG Na, CHENG Mingyan, YAN Zejun. Expression and near-term prognostic predictive value of plasma biomarkers in chronic kidney disease patients with thromboembolism [J]. Laboratory Medicine, 2023, 38(12): 1177-1182.
[13]	. [J]. Laboratory Medicine, 2023, 38(12): 1183-1185.
[14]	. [J]. Laboratory Medicine, 2023, 38(12): 1186-1190.
[15]	. [J]. Laboratory Medicine, 2023, 38(12): 1191-1194.